KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC

被引：54
|
作者：
Cortes, J. [1 ,2 ,3 ,4 ]
Cescon, D. W. [5 ]
Rugo, H. S. [6 ]
Im, S-A. [7 ]
Yusof, M. Md [8 ]
Gallardo, C. [9 ]
Lipatov, O. [10 ]
Barrios, C. H. [11 ]
Perez-Garcia, J. [1 ]
Iwata, H. [12 ]
Masuda, N. [13 ]
Otero, M. Torregroza [14 ]
Gokmen, E. [15 ]
Loi, S. [16 ,17 ]
Guo, Z. [18 ]
Zhou, X. [18 ]
Karantza, V. [18 ]
Pan, W. [18 ]
Schmid, P. [19 ]
机构：
[1] Int Breast Canc Ctr IBCC, Quiron Grp, Madrid, Spain
[2] Int Breast Canc Ctr IBCC, Quiron Grp, Barcelona, Spain
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Hematol Oncol, San Francisco, CA 94143 USA
[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[8] Pantai Hosp, Ctr Canc, Kuala Lumpur, Malaysia
[9] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile
[10] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia
[11] Pontificia Univ Catolica Rio Grande do Sul, Oncol Res Unit, Hosp Sao Lucas, Porto Alegre, RS, Brazil
[12] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[13] Natl Hosp Org Osaka Natl Hosp, Breast Oncol, Dept Surg, Osaka, Japan
[14] Oncomedica SA, Hematol & Oncol, Monteria, Colombia
[15] Ege Univ, Fac Med, Sch Med, Izmir, Turkey
[16] Peter MacCallum Canc Ctr, Div Canc Res, Melbourne, Vic, Australia
[17] Univ Melbourne, Sir Peter MacCallum Dept Med Oncol, Parkville, Vic, Australia
[18] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA
[19] Ctr Expt Canc Med, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页码：S1289 / S1290
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab plus Olaparib vs Pembrolizumab plus Chemotherapy After Induction With Pembrolizumab plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
    Rugo, Hope
    Robson, Mark
    Im, Seock-Ah
    Dalenc, Florence
    Ruiz, Eduardo Yanez
    Im, Young-Hyuck
    Kulyk, Sergii
    Dudnichenko, Oleksandr
    Llinas-Quintero, Nestor
    Saji, Shigehira
    Miyoshi, Yasuo
    Harbeck, Nadia
    Fan, Li
    Mejia, Jaime
    Karantza, Vassiliki
    Cescon, David
    CANCER RESEARCH, 2024, 84 (09)
  • [42] KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Rugo, Hope
    Llombart-Cussac, Antonio
    Andre, Fabrice
    Robson, Mark E.
    Saji, Shigehira
    Harbeck, Nadia
    Schmid, Peter
    Cescon, David
    Ahn, Jin Seok
    Nanda, Rita
    Fan, Li
    Mejia, Jaime Alberto
    Karantza, Vassiliki
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [43] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
    Chung, H.
    Bang, Y.
    Fuchs, C.
    Qin, S.
    Satoh, T.
    Shitara, K.
    Tabernero, J.
    Van Cutsem, E.
    Cao, Z.
    Chen, X.
    Kang, S.
    Shih, C.
    Janjigian, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [44] First-line pembrolizumab plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Kojima, Takashi
    Hara, Hiroki
    Tsuji, Akihito
    Yasui, Hisateru
    Muro, Kei
    Satoh, Taroh
    Ogata, Takashi
    Ishihara, Ryu
    Goto, Masahiro
    Baba, Hideo
    Nishina, Tomohiro
    Han, Shirong
    Sakata, Tomoko
    Yatsuzuka, Naoyoshi
    Doi, Toshihiko
    Kato, Ken
    ESOPHAGUS, 2022, 19 (04) : 683 - 692
  • [45] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
    Wakelee, Heather A.
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    He, Jie
    Gao, Shugeng
    Chen, Ke-Neng
    Dooms, Christophe Alfons
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston Lucas
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Keller, Steven M.
    Samkari, Ayman
    Spicer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [46] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [47] Phase 3 study of epacadostat plus pembrolizumab with or without platinumbased chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715
    Garassino, M.
    Rubin, S.
    Zhao, Y.
    Luo, Y.
    Samkari, A.
    Hui, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S115 - S115
  • [48] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study
    Chung, Hyun Cheol
    Bang, Yung-Jue
    Fuchs, Charles S.
    Qin, Shukui
    Satoh, Taroh
    Shitara, Kohei
    Tabernero, Josep
    Van Cutsem, Eric
    Alsina, Maria
    Cao, Z. Alexander
    Chen, Xinqun
    Bhagia, Pooja
    Shih, Chie-Schin
    Janjigian, Yelena Yuriy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [49] Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    Rudin, Charles M.
    Awad, Mark M.
    Navarro, Alejandro
    Gottfried, Maya
    Peters, Solange
    Csoszi, Tibor
    Cheema, Parneet K.
    Rodriguez-Abreu, Delvys
    Wollner, Mirjana
    Yang, James Chih-Hsin
    Mazieres, Julien
    Orlandi, Francisco J.
    Luft, Alexander
    Gumus, Mahmut
    Kato, Terufumi
    Kalemkerian, Gregory P.
    Luo, Yiwen
    Ebiana, Victoria
    Pietanza, M. Catherine
    Kim, Hye Ryun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) : 2369 - +
  • [50] The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Rha, S. Y.
    Kawazoe, A.
    Bai, Y.
    Xu, J.
    Lonardi, S.
    Metges, J-P.
    Yanez Weber, P. E.
    Wyrwicz, L. S.
    Shen, L.
    Ostapenko, Y. V.
    Bilici, M.
    Chung, H. C.
    Shitara, K.
    Qin, S.
    van Cutsem, E.
    Tabernero, J.
    Li, K.
    Shih, C-S.
    Bhagia, P.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1521 - S1522
12345